1. Androgen profile in Chinese women with polycystic ovary syndrome in their reproductive years 
Zehong Zhou, Rong Li, Jie Qiao 
Reproductive BioMedicine Online 
Volume 35, Issue 3, Pages (September 2017)
DOI: /j.rbmo
Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions

2. Figure 1
Participants in this investigation. PCOS, polycystic ovary syndrome.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions

3. Figure 2
Median, the first and third quartile of the free androgen index and concentrations of total testosterone, androstenedione and sex hormone-binding globulin in different age groups of the polylcystic ovary syndrome (n = 833) and ‘healthy’ reference (n = 821) populations. P-median, median of the values in the PCOS population; Re-median, median of the values in the ‘healthy’ reference population.
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions

4. Figure 3
The prevalence of endocrine and metabolic disorders in the hyperandrogenaemia (n = 288) and non- hyperandrogenaemia (n = 2444) groups defined by the value of 6.0 for free androgen index among the control population. H-A4, androstenedione over 10.8 nmol/l; IR, insulin resistance; central obesity, WHR ≥0.80; L-HDL, low level of serum high-density lipoprotein-cholesterol (HDL-C) < 1.3 mmol/l; MI, menstrual irregularity; PCOM, polycystic ovary morphology; MS, metabolic syndrome; HBP, hypertension; FL, fatty liver. *, Statistically significant differences between the hyperandrogenaemia and non- hyperandrogenaemia group (P < 0.001).
Reproductive BioMedicine Online  , DOI: ( /j.rbmo )
Copyright © 2017 Reproductive Healthcare Ltd. Terms and Conditions